American Association for Cancer Research
10780432ccr102484-sup-supplementary_data.pdf (71.2 kB)

Supplementary Data from MYC Amplification as a Prognostic Marker of Early-Stage Lung Adenocarcinoma Identified by Whole Genome Copy Number Analysis

Download (71.2 kB)
journal contribution
posted on 2023-03-31, 16:26 authored by Reika Iwakawa, Takashi Kohno, Motohiro Kato, Kouya Shiraishi, Koji Tsuta, Masayuki Noguchi, Seishi Ogawa, Jun Yokota

Supplementary Figure S1; Supplementary Table S1.



Purpose: Even in small-sized (≤2 cm in greatest dimension) and/or pathologic stage I lung adenocarcinoma (ADC), a considerable proportion of the patients will relapse within 5 years and show poor prognosis. The purpose of this study was to identify genetic alterations that define prognosis of patients with early-stage lung ADC.Experimental Design: Regions of copy number alterations in 65 small-sized lung ADCs and 40 ADC cell lines were determined by using GeneChip Human Mapping 10-K and 250-K single-nucleotide polymorphism (SNP) arrays, respectively. A copy number assay based on real-time genomic PCR (RT-G-PCR) was done for 60 small-sized lung ADCs and 162 stage I lung ADCs.Results: Several regions on chromosomes 5p, 7p, 8q, and 14q were frequently (>10%) amplified in both small-sized ADCs and lung ADC cell lines. In particular, the MYC gene was mapped in the minimum common region at chromosome 8q24.21, and therefore was indicated to be a target of gene amplification in lung ADCs. MYC amplification correlated with poor prognosis (P = 0.031) of patients with small-sized ADCs. MYC amplification detected by SNP array analysis was well reproduced by RT-G-PCR analysis. Therefore, to investigate the utility of MYC amplification as a prognostic marker for early-stage lung ADCs, 162 stage I lung ADCs were subjected to the analysis. MYC amplification was associated with relapse-free survival in these patients (P = 0.013 by multivariate Cox proportional hazard model analysis).Conclusions: These results strongly indicate that MYC amplification is a prognostic marker of patients with early-stage lung ADCs. Clin Cancer Res; 17(6); 1481–9. ©2010 AACR.

Usage metrics

    Clinical Cancer Research



    Ref. manager